Barclays
ELTX icon

Barclays’s Elicio Therapeutics ELTX Stock Holding History

Barclays’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.3K Buy
6,755
+4,979
+280% +$13.8K ﹤0.01% 4807
2026
Q2 		$6.94K Buy
+1,776
New +$17.8K ﹤0.01% 4745
2023
Q2 		– Sell
-362
Closed -$2.1K – 4679
2023
Q1 		$2.1K Hold
362
– – ﹤0.01% 4887
2022
Q4 		$2.94K Hold
362
– – ﹤0.01% 5057
2022
Q3 		$3K Hold
362
– – ﹤0.01% 4576
2022
Q2 		$4K Sell
362
-353
-49% -$5.64K ﹤0.01% 4811
2022
Q1 		$15K Buy
+715
New +$16.1K ﹤0.01% 4516

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Leonteq Securities AG
Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Meyer Handelman Company
Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Barclays's ELTX Position: Q3 2026 in Review

Barclays increased its Elicio Therapeutics (ELTX) stake by 280% in Q3 2026, buying an estimated $13.8K and bringing the position to 6,755 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4807.

Barclays first reported a position in ELTX in Q1 2022 and has held it in 7 quarters since. The position peaked at $15K in Q1 2022. 27 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Barclays held 6,755 shares of Elicio Therapeutics worth $12.3K as of Q3 2026.
  • Barclays bought 4,979 Elicio Therapeutics shares in Q3 2026, an estimated $13.8K.
  • Elicio Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4807 holding.
  • Barclays first reported a position in Elicio Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • Barclays's Elicio Therapeutics position peaked at $15K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.